keyword
MENU ▼
Read by QxMD icon Read
search

Guanfacine

keyword
https://www.readbyqxmd.com/read/29659126/guanfacine-decreases-symptoms-of-cannabis-withdrawal-in-daily-cannabis-smokers
#1
Margaret Haney, Ziva D Cooper, Gillinder Bedi, Evan Herrmann, Sandra D Comer, Stephanie Collins Reed, Richard W Foltin, Frances R Levin
The α2a-adrenergic agonist, lofexidine, reduced cannabis withdrawal-related sleep disruption in the laboratory, but side effects (e.g. fatigue, hypotension) limit its utility as a treatment for cannabis use disorder. This study tested the potential efficacy and tolerability of a daily bedtime administration of the FDA-approved α2a-adrenergic agonist, guanfacine, in a human laboratory model of cannabis use disorder. Daily, nontreatment-seeking cannabis smokers (13M, 2F) completed a within-subject study comprising two 9-day inpatient study phases...
April 16, 2018: Addiction Biology
https://www.readbyqxmd.com/read/29619866/enteral-guanfacine-to-treat-severe-anxiety-and-agitation-complicating-critical-care-after-cardiac-surgery
#2
Habib Srour, Komal Pandya, Alex Flannery, Kevin Hatton
This article is the first reported case describing the off-label use of enteral immediate-release guanfacine, a long-acting α-2 adrenergic agonist most commonly used in the treatment of attention-deficit hyperactivity disorder, for sedation in a patient with severe anxiety and agitation limiting mechanical ventilation weaning several days after cardiac surgery. In this case, after several days of unsuccessful attempts to control his agitation and anxiety with conventional therapies, guanfacine therapy was initiated, and the patient was rapidly weaned from all other sedatives and mechanical ventilation shortly thereafter...
April 1, 2018: Seminars in Cardiothoracic and Vascular Anesthesia
https://www.readbyqxmd.com/read/29540864/a-randomized-placebo-controlled-trial-of-extended-release-guanfacine-in-children-with-autism-spectrum-disorder-and-adhd-symptoms-an-analysis-of-secondary-outcome-measures
#3
Laura C Politte, Lawrence Scahill, Janet Figueroa, James T McCracken, Bryan King, Christopher J McDougle
In a prior report, we showed that extended-release guanfacine (GEXR) is safe and effective for children with autism spectrum disorder (ASD) accompanied by ADHD symptoms. Here, we examine the impact of GEXR on oppositional behavior, anxiety, repetitive behavior, and sleep disturbance. Sixty-two subjects with ASD (53 boys, 9 girls; ages 5-14 years) were randomly assigned to GEXR (n = 30) or placebo (n = 32) for 8 weeks. Outcomes include the Home Situation Questionnaire-Modified for ASD (HSQ-ASD), Anxiety scale of the Child and Adolescent Symptom Inventory (CASI), Children's Yale-Brown Obsessive-Compulsive Scale-Modified for ASD (CYBOCS-ASD), and Children's Sleep Habits Questionnaire (CSHQ)...
February 27, 2018: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29476896/systemic-administration-of-guanfacine-improves-food-motivated-impulsive-choice-behavior-primarily-via-direct-stimulation-of-postsynaptic-%C3%AE-2a-adrenergic-receptors-in-rats
#4
Kouhei Nishitomi, Koji Yano, Mika Kobayashi, Kohei Jino, Takuya Kano, Naotaka Horiguchi, Shunji Shinohara, Minoru Hasegawa
Impulsive choice behavior, which can be assessed using the delay discounting task, is a characteristic of various psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). Guanfacine is a selective α2A -adrenergic receptor agonist that is clinically effective in treating ADHD. However, there is no clear evidence that systemic guanfacine administration reduces impulsive choice behavior in the delay discounting task in rats. In the present study, we examined the effect of systemic guanfacine administration on food-motivated impulsive choice behavior in rats and the neuronal mechanism underlying this effect...
June 1, 2018: Behavioural Brain Research
https://www.readbyqxmd.com/read/29472646/interaction-between-noradrenergic-and-cholinergic-signaling-in-amygdala-regulates-anxiety-and-depression-related-behaviors-in-mice
#5
Yann S Mineur, Emma L Cahuzac, Tenna N Mose, Matthew P Bentham, Margreet E Plantenga, David C Thompson, Marina R Picciotto
Medications that target the noradrenergic system are important therapeutics for depression and anxiety disorders. More recently, clinical studies have shown that the α2-noradrenergic receptor (α2AR) agonist guanfacine can decrease stress-induced smoking relapse during acute abstinence, suggesting that targeting the noradrenergic system may aid in smoking cessation through effects on stress pathways in the brain. Acetylcholine (ACh), like the nicotine in tobacco, acts at nicotinic acetylcholine receptors (nAChRs) to regulate behaviors related to anxiety and depression...
February 22, 2018: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29460165/efficacy-and-safety-of-drugs-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-a-network-meta-analysis
#6
Sarah C O S Padilha, Suzane Virtuoso, Fernanda S Tonin, Helena H L Borba, Roberto Pontarolo
The aim of this study is to gather evidence of head-to-head double-blind randomized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder (ADHD) in children and adolescents. A systematic review was conducted by two independent reviewers in ten electronic databases (PROSPERO register CRD42016043239). Methodological quality of included studies was evaluated according to the Jadad scale. Network meta-analyses were performed including double-blinded head-to-head trials comparing active allopathic drugs in patients (0-18 years old) diagnosed with ADHD...
February 19, 2018: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/29456930/review-of-the-evidence-for-the-management-of-co-morbid-tic-disorders-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#7
REVIEW
Michael O Ogundele, Hani F Ayyash
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children and adolescents, with prevalence ranging between 5% and 12% in the developed countries. Tic disorders (TD) are common co-morbidities in paediatric ADHD patients with or without pharmacotherapy treatment. There has been conflicting evidence of the role of psychostimulants in either precipitating or exacerbating TDs in ADHD patients. We carried out a literature review relating to the management of TDs in children and adolescents with ADHD through a comprehensive search of MEDLINE, EMBASE, CINAHL and Cochrane databases...
February 8, 2018: World Journal of Clinical Pediatrics
https://www.readbyqxmd.com/read/29442229/long-term-safety-and-efficacy-of-guanfacine-extended-release-in-children-and-adolescents-with-adhd
#8
Michael Huss, Bryan Dirks, Joan Gu, Brigitte Robertson, Jeffrey H Newcorn, J Antoni Ramos-Quiroga
Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Participants received dose-optimized GXR (1-7 mg/day) for up to 2 years. Of 215 enrolled participants, 214 were included in the safety population and 133 completed the study. Participants' mean age was 11.7 years and 73.8% were male. Overall, 177 participants (82.7%) experienced a treatment-emergent adverse event (TEAE)...
February 13, 2018: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/29436486/randomised-double-blind-placebo-controlled-crossover-study-of-single-dose-guanfacine-in-unilateral-neglect-following-stroke
#9
Edwin S Dalmaijer, Korina M S Li, Nikos Gorgoraptis, Alexander P Leff, David L Cohen, Andrew D Parton, Masud Husain, Paresh A Malhotra
OBJECTIVE: Unilateral neglect is a poststroke disorder that impacts negatively on functional outcome and lacks established, effective treatment. This multicomponent syndrome is characterised by a directional bias of attention away from contralesional space, together with impairments in several cognitive domains, including sustained attention and spatial working memory. This study aimed to test the effects of guanfacine, a noradrenergic alpha-2A agonist, on ameliorating aspects of neglect...
February 7, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29411149/pharmacological-treatment-of-attention-deficit-hyperactivity-disorder-during-pregnancy-and-lactation
#10
REVIEW
Asher Ornoy
INTRODUCTION: Attention deficit/hyperactivity disorder (ADHD) is a neurobehavioral problem found in 2-5% of adults. Stimulants and drugs that affect the dopaminergic, noradrenergic and/or serotonergic systems are effective treatment and are increasingly prescribed to women at child bearing age. It is consequently important that reliable information on the safety of these drugs in pregnancy is available so that appropriate therapeutic choices can be made. RESULTS: The data on stimulants (methylphenidate and amphetamines) are generally showing that there is no increase in the rate of major congenital anomalies...
February 6, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29398934/pharmacotherapy-of-emotional-and-behavioral-symptoms-associated-with-autism-spectrum-disorder-in-children-and-adolescents
#11
Ekaterina Stepanova, Susannah Dowling, Molly Phelps, Robert L Findling
Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD...
December 2017: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/29335879/current-approaches-and-new-developments-in-the-pharmacological-management-of-tourette-syndrome
#12
REVIEW
Julio Quezada, Keith A Coffman
Tourette syndrome (TS) is a neurodevelopmental disorder of unknown etiology characterized by spontaneous, involuntary movements and vocalizations called tics. Once thought to be rare, TS affects 0.3-1% of the population. Tics can cause physical discomfort, emotional distress, social difficulties, and can interfere with education and desired activities. The pharmacologic treatment of TS is particularly challenging, as currently the genetics, neurophysiology, and neuropathology of this disorder are still largely unknown...
January 2018: CNS Drugs
https://www.readbyqxmd.com/read/29313415/a-controlled-trial-of-extended-release-guanfacine-and-psychostimulants-on-executive-function-and-adhd
#13
Judy P M van Stralen
OBJECTIVE: To evaluate the effectiveness of guanfacine extended-release (GXR) versus placebo as adjunct therapy to usual care stimulant therapy in improving executive function in children aged 6 to 12 years diagnosed with ADHD. METHOD: In this single center, double-blind placebo-controlled crossover trial, subjects continued to take their psychostimulant and were randomly assigned at baseline to receive active treatment or placebo first. Efficacy measures included Behavioural Rating Inventory of Executive Function (BRIEF-P), ADHD Rating Scale IV (ADHD-RS IV), and Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) scales...
January 1, 2018: Journal of Attention Disorders
https://www.readbyqxmd.com/read/29298540/healthcare-utilization-and-costs-of-children-with-attention-deficit-hyperactivity-disorder-initiating-atomoxetine-versus-extended-release-guanfacine
#14
Cliff Molife, Virginia S Haynes, Allen Nyhuis, Douglas E Faries, Steve Gelwicks, Douglas K Kelsey, Carlos I Alatorre
OBJECTIVES: To compare 1-year direct healthcare costs and utilization among children and adolescents initiating non-stimulant medications atomoxetine (ATX) or extended-release guanfacine (GXR). METHODS: In this retrospective, observational cohort study, children and adolescents aged 6-17 years with attention deficit/hyperactivity disorder (ADHD) who had ≥1 prescription claim for ATX or GXR between December 31, 2009 and January 1, 2011 were identified in the MarketScan Commercial or Multi-State Medicaid claims databases...
April 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29290742/off-label-prescribing-trends-for-adhd-medications-in-very-young-children
#15
Shannon G Panther, Alice M Knotts, Tamara Odom-Maryon, Kenneth Daratha, Teri Woo, Tracy A Klein
OBJECTIVE: This study examines off-label medication prescribing use and trends in children on Medicaid with ADHD with particular focus on the very young (under age 6 years). METHODS: This was an observational cohort study and retrospective analysis of ADHD medication prescriptions from Oregon Medicaid records (N = 83,190) in 2012. Manufacturer prescribing information was used to determine off-label designation. Children ages 3 to 18 years at the time of prescription who had continuous Medicaid enrollment of at least 10 months during the index year of 2012 were included in the sample frame...
November 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29282674/correction-to-development-of-guanfacine-extended-release-dosing-strategies-in-children-and-adolescents-with-adhd-using-a-physiologically-based-pharmacokinetic-model-to-predict-drug-drug-interactions-with-moderate-cyp3a4-inhibitors-or-inducers
#16
Aiqun Li, Karen Yeo, Devin Welty, Haojing Rong
The article "Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a PhysiologicallyBased Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers", written by Aiqun Li, Karen Yeo, Devin Welty, Haojing Rong, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 02nd November, 2017 without open access.
April 2018: Paediatric Drugs
https://www.readbyqxmd.com/read/29237331/autism-spectrum-disorder-consensus-guidelines-on-assessment-treatment-and-research-from-the-british-association-for-psychopharmacology
#17
Oliver D Howes, Maria Rogdaki, James L Findon, Robert H Wichers, Tony Charman, Bryan H King, Eva Loth, Gráinne M McAlonan, James T McCracken, Jeremy R Parr, Carol Povey, Paramala Santosh, Simon Wallace, Emily Simonoff, Declan G Murphy
An expert review of the aetiology, assessment, and treatment of autism spectrum disorder, and recommendations for diagnosis, management and service provision was coordinated by the British Association for Psychopharmacology, and evidence graded. The aetiology of autism spectrum disorder involves genetic and environmental contributions, and implicates a number of brain systems, in particular the gamma-aminobutyric acid, serotonergic and glutamatergic systems. The presentation of autism spectrum disorder varies widely and co-occurring health problems (in particular epilepsy, sleep disorders, anxiety, depression, attention deficit/hyperactivity disorder and irritability) are common...
January 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29201635/successful-use-of-guanfacine-in-a-patient-with-chronic-refractory-cough-a-case-report
#18
Gregory W Kirschen, Howard Kirschen, Edward Gabalski, Jonathan M Waxner, Agnes Wohl
Chronic idiopathic cough is a common and often frustrating complaint for patients as well as providers. When common etiologies of cough are ruled out and/or do not respond to usual treatments, neurogenic cough should be considered as a diagnosis of exclusion. Here, we report on a 58-year-old woman with an 8-year history of chronic, treatment-refractory cough of unknown etiology that we diagnosed as neurogenic cough and successfully treated with guanfacine monotherapy, with rapid and durable improvement in symptoms...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29186993/medication-use-in-adults-with-attention-deficit-hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states
#19
Zhou Zhou, Zheng-Yi Zhou, Sneha S Kelkar, Vanja Sikirica, Jipan Xie, Regina Grebla
OBJECTIVE: To examine real-world prescription medication usage among commercially-insured adults with attention deficit/hyperactivity disorder (ADHD) in the US. METHODS: Adults with ADHD who received ≥1 ADHD medication during 2013 were identified from a large US claims database. Combination therapy was defined as an overlap of ≥30 days between the index (first treatment ≥30 days in 2013) and another medication(s). Patients were classified into six groups: long-acting (LA) monotherapy, short-acting (SA) monotherapy, LA + LA, SA + SA, LA + SA, and >2 therapies...
April 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29180967/efficacy-and-tolerability-of-different-interventions-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#20
Ruiling Luan, Zhiling Mu, Fang Yue, Shaoying He
Background: Our study is an analysis of multiple publications involving assessing the comparable efficacy and tolerability of six interventions, which are lisdexamfetamine dimesylate (LDX), atomoxetine (ATX), methylphenidate (MPH), clonidine hydrochloride (CLON), guanfacine extended release (GXR), and bupropion, for young patients (6-18 years old) suffering from attention deficit hyperactivity disorder (ADHD). Methods: A conventional meta-analysis (MA) was performed to give direct comparisons and a network meta-analysis (NMA) was used to show the combination of direct and indirect evidence...
2017: Frontiers in Psychiatry
keyword
keyword
7575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"